COMPANY PROFILE

3Spine

Explore full profile

Solving One of the Greatest Problems in Medicine

Chattanooga, United StatesFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About 3Spine

3Spine is a medical technology company specializing in the development and clinical testing of innovative treatments for lumbar spine conditions, particularly degenerative disc disease. The company operates in the healthcare and medical devices market, focusing on providing advanced solutions for spinal health. 3Spine's core product is a lumbar artificial disc replacement system, which aims to improve patient outcomes compared to traditional spinal fusion surgeries. The company serves patients suffering from degenerative spine conditions and collaborates with healthcare providers and research institutions to validate its treatments through rigorous clinical trials.

3Spine's business model revolves around the development, clinical validation, and eventual commercialization of its spinal treatment technologies. The company generates revenue through the sale of its medical devices and potentially through partnerships and licensing agreements with other healthcare entities. By focusing on clinical evidence and patient outcomes, 3Spine aims to establish its products as a superior alternative to existing treatments in the market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Chattanooga, United States
Employees: 15
Open positions: None listed
Dealroom signal: 26.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	Jun 2024	$8.2M	—	Undisclosed	↗
SERIES COther financing	Mar 2022	$33M	$132M	Undisclosed	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

3Spine website traffic

Latest recorded traffic for 3Spine is 1.9K monthly website visits, up 533.3% over the last three months. 3Spine's team grew 0% over the past year.

Latest monthly visits1.9K 3-month web change+533.3% 1-year team growth0%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational	14	$103M	$253M
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational
ETElastrin TherapeuticsReversing diseases by targeting damaged elastin fibers	Simpsonville, United States	Operational